The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

On a recent weekday evening, Ashly Richards helped her 13-year-old son, Case, with homework. He did math problems and some ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

U.S. District Judge Matthew J. Kacsmaryk for the Northern District of Texas vacated portions of the 2024 final rule for ...

Mini meals with bite size portions are meant to appeal to people taking GLP-1 weight-loss drugs that reduce appetite.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru ...

Democrats aren't rushing to play ball with Republicans on a bipartisan health care package after passage of the president's ...

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.